Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Pappadopulos

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Journal of Child and Adolescent Psychopharmacology|October 12, 2013
Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorderRobert L Findling, Idil Cavuş, Elizabeth Pappadopulos, et al.
Journal of Child and Adolescent Psychopharmacology|October 12, 2013
Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension studyRobert L Findling, Idil Cavuş, Elizabeth Pappadopulos, et al.
Journal of Clinical Psychopharmacology|August 18, 2017
Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive DisorderMartin A Katzman, Andrew A Nierenberg, Dalia B Wajsbrot, et al.
Current Medical Research and Opinion|August 3, 2019
Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world studyRoger S McIntyre, Rita Prieto, Patricia Schepman, et al.
Journal of Multidisciplinary Healthcare|May 3, 2021
Economic and Humanistic Burden Associated with Depression and Anxiety Among Adults with Non-Communicable Chronic Diseases (NCCDs) in the United StatesEric Armbrecht, Ruchit Shah, Gregory W Poorman, et al.
Sleep Medicine|February 27, 2022
Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorderThomas Roth, Russell Rosenberg, Charles M Morin, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 30, 2011
Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profilesDavid E Kemp, Onur N Karayal, Joseph R Calabrese, et al.
Journal of Medical Economics|November 1, 2019
Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United States-based retrospective claims database analysisSripal Bangalore, Ruchitbhai Shah, Xin Gao, et al.
Schizophrenia Bulletin|June 6, 2002
"Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settingsElizabeth Pappadopulos, Peter S Jensen, Sarah B Schur, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|January 25, 2003
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a reviewSarah B Schur, Lin Sikich, Robert L Findling, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Journal of Child and Adolescent Psychopharmacology|October 12, 2013
Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorderRobert L Findling, Idil Cavuş, Elizabeth Pappadopulos, et al.
Journal of Child and Adolescent Psychopharmacology|October 12, 2013
Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension studyRobert L Findling, Idil Cavuş, Elizabeth Pappadopulos, et al.
Journal of Clinical Psychopharmacology|August 18, 2017
Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive DisorderMartin A Katzman, Andrew A Nierenberg, Dalia B Wajsbrot, et al.
Current Medical Research and Opinion|August 3, 2019
Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world studyRoger S McIntyre, Rita Prieto, Patricia Schepman, et al.
Journal of Multidisciplinary Healthcare|May 3, 2021
Economic and Humanistic Burden Associated with Depression and Anxiety Among Adults with Non-Communicable Chronic Diseases (NCCDs) in the United StatesEric Armbrecht, Ruchit Shah, Gregory W Poorman, et al.
Sleep Medicine|February 27, 2022
Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorderThomas Roth, Russell Rosenberg, Charles M Morin, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 30, 2011
Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profilesDavid E Kemp, Onur N Karayal, Joseph R Calabrese, et al.
Journal of Medical Economics|November 1, 2019
Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United States-based retrospective claims database analysisSripal Bangalore, Ruchitbhai Shah, Xin Gao, et al.
Schizophrenia Bulletin|June 6, 2002
"Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settingsElizabeth Pappadopulos, Peter S Jensen, Sarah B Schur, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|January 25, 2003
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a reviewSarah B Schur, Lin Sikich, Robert L Findling, et al.
Pageof 4